Human Vaccine Adjuvants Market is expected to reach US$ 4,489.23 million by 2030

By Type, the Particulate Adjuvant Segment is expected to Dominate Human Vaccine Adjuvants Market During 2022–2030

According to our new research study on "Human Vaccine Adjuvants Market Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis," the market value is projected to grow from US$ 1,571.41 million in 2022 to US$ 4,489.23 million by 2030. The human vaccine adjuvants market is further anticipated to record a CAGR of 14.0% from 2022 to 2030. Key factors driving the human vaccine adjuvants market growth include the rising prevalence of chronic diseases and the growing focus on immunization programs. However, the manufacturing complexities and regulatory challenges hinder the market growth.

The expanding pharmaceutical industry is expected to positively influence the demand for adjuvants as they can improve the efficacy and safety of vaccines. The pharmaceutical industry's increasing focus on infectious diseases, cancer, and autoimmune disorders provides a platform for developing personalized vaccines and adjuvants targeted at these specific disease areas. This offers an opportunity for adjuvant manufacturers to develop specialized adjuvants to enhance the immune response to vaccines for these diseases.

Human Vaccine Adjuvants Market, by Region, 2022 (%)

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00020517

Source: The Insight Partners Analysis

The US has one of the most R&D-intensive pharmaceutical industries globally. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the North America market (US and Canada) remained the world's largest market with a 49.1% share, well ahead of Europe, China, and Japan. The US is the global leader in innovative R&D investments, and the country produced over half of the world's new molecules in the last decade. Additionally, as per EFPIA, in 2021, North America accounted for 49.1% of global pharmaceutical sales, compared with 23.4% for Europe.

Similarly, according to the EFPIA, the Brazilian, Chinese, and Indian pharmaceutical industries grew by 11.7%, 6.7%, and 11.8% during 2016–2021, respectively, compared to the top five European Union markets and the US market, which recorded an average market growth of 5.8% and 5.6%, respectively. Furthermore, as per the India Brand Equity Foundation (IBEF), India is a major and rising global pharmaceutical industry player. The country is the world's largest trader of generic medications, accounting for nearly 20% of the worldwide supply by volume. It supplies ~50% of the global vaccination demand. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. Based on official figures from the Indian government, the pharmaceutical sector in India is valued at nearly US$ 50 billion, of which over US$ 25 billion is derived from exports. India accounts for ~20% of the world's generic medicine exports. Further, Japan is one of the largest pharmaceutical markets in the world. According to the Ministry of Health, Labor and Welfare's (MHLW) Annual Pharmaceutical Production Statistics, the Japanese market for prescription and nonprescription pharmaceuticals in 2020 was US$ 107 billion.

As the industry continues to evolve and innovate, there is an increasing demand for adjuvants that can support the development of personalized vaccines, driving significant growth and investment in the human vaccine adjuvants market. Thus, the growing pharmaceutical industry worldwide will likely create lucrative growth opportunities for the human vaccine adjuvants market in the coming years.  

Novartis AG, Dynavax Technologies Corp, CSL Ltd, Seppic SA, SPI Pharma Inc, Hawaii Biotech Inc, Croda International Plc, Novavax Inc, Phibro Animal Health Corp, and Creative Biolabs Inc are among the key companies operating in the human vaccine adjuvants market. The companies have been implementing both organic strategies (such as product launches and product approvals) and inorganic strategies (such as expansions, collaborations, and partnerships) to secure growth in the market. For instance, in October 2023, SPI Pharma Inc. and Q-Vant Biosciences Inc. announced a partnership that combines Q-Vant's leadership in sustainable saponin extraction technology with SPI's global reach and servicing expertise in the pharmaceutical industry. The arrangement includes investment in the expansion of Q-Vant’s proprietary 100% sustainable Q-SAP technology and an exclusive commercial agreement to accelerate the global adoption of their saponin adjuvants for veterinary and human vaccine formulations.

The report segments the human vaccine adjuvants market as follows:

Based on type, the human vaccine adjuvants market is segmented into particulate adjuvants, emulsion adjuvants, combination adjuvants, and others. The particulate adjuvant segment held a larger share of the market in 2022. However, the emulsion adjuvants segment is expected to register the highest CAGR in the market from 2022 to 2030. Particulate adjuvants consist of particles, often of nanometer or micrometer size, designed to mimic pathogens or cellular structures, stimulating a robust immune response. These adjuvants enhance antigen uptake by immune cells and promote immune activation. Notable examples of particulate adjuvants include aluminum salts (Alum), which have been used for decades in human vaccines to enhance antibody responses, and newer developments such as virus-like particles (VLPs) and nanoparticle-based adjuvants. 

By application, the human vaccine adjuvants market is segmented into influenza, hepatitis, human papillomavirus (HPV), and others. The influenza segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Influenza vaccines are crucial for preventing seasonal flu outbreaks and potential pandemics. They target a rapidly evolving virus, requiring continual vaccine updating to match circulating strains. Adjuvants used in influenza vaccines enhance immune responses, particularly in high-risk populations such as the elderly or immunocompromised individuals. They also support the development of broadly protective, cross-reactive immune responses.

In terms of end user, the human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Pharmaceutical and biotechnology companies play a central role in the research, development, and commercialization of vaccines, including adjuvanted vaccine formulations, targeting diverse infectious diseases and health conditions. These companies are at the forefront of vaccine innovation, driving the discovery and optimization of adjuvant technologies, vaccine candidates, and adjuvanted vaccine formulations through preclinical and clinical development stages.

Geographically, the human vaccine adjuvants market is segmented into North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Russia, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: Content Team 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com